Focus shifts to Keytruda amid competition from Gilead and shrinking market.
October 2, 2017Share
September 13, 2017Share
Janssen axes hep C development with Achillion
August 1, 2017Share
AbbVie, Gilead target sick hepatitis C patients in EU
July 20, 2017Share
Vosevi is aimed at tough to treat patients.
Gilead’s latest hep C combo approved in US
June 26, 2017Share
Regulators finally back Merck KGaA oral MS drug
May 10, 2017Share
US authorities suspicious over marketing, rebates and payment support programmes.
US authorities probe marketing of J&J drugs
April 26, 2017Share
Former health secretary says scandal was “criminal” cover-up.
Call for inquiry into NHS contaminated blood scandal
April 24, 2017Share
Trial backs patient-friendly regime in tough to treat strain.
AbbVie takes aim at Gilead and BMS with 8-week hep C treatment